![](https://investorshub.advfn.com/uicon/496411.png?cb=1505403973)
Friday, November 30, 2018 8:57:36 PM
This gender gap in efficacy did not show up in the Knee or Foot Trial.
Seems more likely that those researchers simply didn't identify gender.
I am suspicious of the Koneru brothers. I don't think they know how to run a good clinical trial. I think they would have combined male and female data if they could, but the combination resulted in less than statistical significant efficacy, so they tried to cherry-pick and split the data by gender, hoping to get THAT by the FDA using smoke and mirrors.
The Back Trial shows Substantial Equivalency for women
Based on the sketchy wording in BIEL's press release, I also think the FDA just told BIEL "you can't use the knee and foot data for a predicate device unless you scrub that data by gender." But who knows -- BIEL management never tells the whole story and never tells us what the FDA actually said, always keeping shareholders in the dark. Their disclosure policies are insulting.
Let's see the rejection letter so we can stop guessing.
Kona Gold Beverage Inc. Signs Letter of Intent with Bemax, Inc. to Sell Kona Gold, LLC • BMXC • Aug 7, 2024 10:00 AM
Btab Ecommerce Group, Inc. Launches Investor Connect AI Chatbot for Enhanced Investor Engagement and Lead Generation • BBTT • Aug 7, 2024 9:00 AM
Hydromer, Inc. Announces Preliminary Unaudited Second Quarter 2024 Financial Results and Provides Business Update • HYDI • Aug 7, 2024 8:52 AM
North Bay Resources Announces Mt. Vernon Gold Mine Startup, Sierra County, California • NBRI • Aug 5, 2024 9:00 AM
Fifty 1 Labs, Inc. and All-In-Extracts Announce Joint Venture to Develop and Release New Testosterone Boosting Supplement • BLEG • Aug 5, 2024 8:30 AM
Kona Gold Beverages, Inc. Announces Strategic Initiatives and Corporate Direction Changes • KGKG • Aug 2, 2024 2:00 PM